Delcath Systems Inc
DCTHDelcath Systems Inc (DCTH) is a healthcare company specializing in innovative, proprietary targeted drug delivery systems for the treatment of cancer. Their flagship product, the HEPATIC CHEMOSAT Delivery System, is designed to deliver high doses of chemotherapy directly to the liver, aiming to improve treatment outcomes for hepatic cancers. The company focuses on developing and commercializing therapies that enhance the efficacy of chemotherapy while minimizing systemic side effects.
Company News
Delcath Systems (DCTH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
The mean of analysts' price targets for Delcath Systems (DCTH) points to a 197.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The mean of analysts' price targets for Delcath Systems (DCTH) points to a 201.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Delcath Systems (DCTH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
